Table 3 Prospective data analysis of CD4 T cell subsets
From: Immune signatures for HIV-1 and HIV-2 induced CD4+T cell dysregulation in an Indian cohort
A Sampling and analysis of all prospective data (n = 10) | |||||||||
ART-receiving HIV-1 infected individuals no. | % of Treg (CD25 high CD127 low ) | % of Effector subset (CD127 − CD25 − ) | % of Naïve/Memory subset(CD127 + CD25 low/− ) | ||||||
TP-1 | TP-2 | TP-3 | TP-1 | TP-2 | TP-3 | TP-1 | TP-2 | TP-3 | |
1 | 17.4 | 19.20 | SNA | 8.61 | 9.51 | SNA | 73.20 | 70.90 | SNA |
2 | 22.7 | 21.60 | 18.7 | 18.10 | 16.40 | 17.40 | 58.70 | 61.20 | 63.00 |
3 | 16.5 | SNA | 15.1 | 12.30 | SNA | 11.70 | 70.50 | SNA | 73.00 |
4 | 25.2 | 24.00 | SNA | 15.90 | 15.20 | SNA | 57.50 | 56.90 | SNA |
5 | 18.6 | 13.70 | 16.0 | 10.20 | 9.36 | 9.19 | 70.90 | 73.70 | 72.60 |
6 | 17.7 | 16.30 | 15.8 | 12.10 | 11.40 | 7.88 | 69.70 | 71.20 | 71.10 |
7 | 17.3 | 16.20 | 17.0 | 12.30 | 10.45 | 11.90 | 69.40 | 76.30 | 70.80 |
8 | 18.7 | 17.10 | SNA | 10.70 | 9.26 | SNA | 69.80 | 70.20 | SNA |
9 | 23.1 | SNA | 21.7 | 16.50 | SNA | 10.80 | 59.90 | SNA | 67.50 |
10 | 15.7 | 7.65 | SNA | 13.30 | 3.21 | SNA | 70.90 | 89.00 | SNA |
B Comparison of CD4+ T cells subsets in ART-treated HIV-1 infected individuals (n = 8) from group 1 (TP-1 and TP-2) | |||||||||
Non-parametric paired T test (Wilcoxon matched paired test) | % of Treg (CD25 high CD127 low ) | % of Effector subset (CD127 − CD25 − ) | % of Naïve/Memory subset (CD127 + CD25 low/− ) | ||||||
P value | 0.1094 | 0.0547 | 0.1094 | ||||||
P value summary (P < 0.05) | ns | ns | ns | ||||||
C Comparison of CD4+ T cells subsets in ART-treated HIV-1 infected individuals (n = 4) from group 3 (TP1, TP2 and TP3) | |||||||||
Repeated Measures ANOVA | % of Treg (CD25 high CD127 low ) | % of Effector subset (CD127 − CD25 − ) | % of Naïve/Memory subset (CD127 + CD25 low/− ) | ||||||
P value | 0.0978 | 0.2192 | 0.0724 | ||||||
P value summary (P < 0.05) | ns | ns | ns | ||||||